(Q42615641)

3 November 2017

title

An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder (English)

1 reference

3 November 2017

main subject

irritable bowel syndrome

1 reference

Alicia Kaplan

1

1 reference

3 November 2017

Michael D Franzen

2

1 reference

3 November 2017

P V Nickell

3

1 reference

3 November 2017

Danielle Ransom

4

1 reference

3 November 2017

Paul J Lebovitz

5

1 reference

3 November 2017

publication date

20 September 2013

1 reference

International Journal of Psychiatry in Clinical Practice

3 November 2017

published in

1 reference

3 November 2017

volume

18

1 reference

3 November 2017

issue

1

1 reference

3 November 2017

page(s)

11-15

1 reference

Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

The role of stress in symptom exacerbation among IBS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Effect size estimates: current use, calculations, and interpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Biopsychosocial issues in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

The placebo effect in irritable bowel syndrome trials: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Should excessive worry be required for a diagnosis of generalized anxiety disorder? Results from the US National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.838632

10.3109/13651501.2013.838632

21 January 2018

Identifiers

DOI

1 reference

3 November 2017

1 reference